Boston Scientific Shares Jump as Revised Earnings Outlook Exceeds Expectations

Shares of Boston Scientific (NYSE: BSX) surged more than 1% during premarket trading on Wednesday, propelled by the company's revised earnings outlook for the year.

This upward revision has outstripped what analysts had been anticipating, leading to a positive market reaction.

For the Q3, Boston Scientific reported an impressive earnings per share (EPS) of $0.63, eclipsing analysts' expectations, which were pegged at $0.59. Revenue for the period reached $4.21 billion, well above the forecasted $4.04 billion, highlighting the company's robust financial performance. Breaking down the revenue sources, endoscopy net sales amounted to $678 million, marking a year-over-year increase of 7.8%, slightly outpacing the expected $675.9 million. Meanwhile, cardiology net sales soared by 29% year-over-year to $2.13 billion, significantly surpassing the $2 billion estimate.

Looking ahead, Boston Scientific is projecting EPS for the fourth quarter of 2024 to fall between $0.64 and $0.66—a figure that aligns with analysts' forecasts. More excitingly, for the full year 2024, the company has raised its EPS guidance to a range of $2.45 to $2.47, an improvement from its earlier estimate of $2.38 to $2.42, thereby exceeding the consensus expectation of $2.41.

Mike Mahoney, the chairman and CEO of Boston Scientific, attributed this remarkable performance to “the strength of our talented global team, differentiated portfolio, and category leadership strategy.” He added, “We continue to gain momentum driven by our product pipeline, clinical evidence, and commercial execution that position us well for the long term.”